B+
Bull case
25%
Probability
Target price
$5.40
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
MNKD
MannKindBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+74.8
Score
AI commentary
News tone is constructive around record revenue, regulatory approvals, and pipeline milestones but tempered by the GAAP loss, elevated costs, cash obligations, Afrezza softness, and uncertainty around the second-half revenue profile. Social sentiment, options skew, short interest, and employee sentiment are unavailable rather than neutral; the zero values are placeholders for unavailable packet data. Low analyst coverage and loose peers reduce confidence. The setup remains event-driven and suitable for monitoring rather than aggressive conviction.
RankAlpha Sentiment Codex - 2026-08-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31eventFUROSCIX ReadyFlow commercial launchHigh impact
FDA approved the ReadyFlow autoinjector on July 23, 2026, with commercial availability expected in late August. Q2 FUROSCIX sales were $22.2 million, while integrated-delivery-network doses and nephrology units increased sequentially. [#SEC-8K-2026-08-05]
2026-12-31catalystAfrezza pediatric uptakeHigh impact
The pediatric indication is approved, with prescriptions from all 20 priority accounts and one-third of the top 100 pediatric insulin writers. Sustained uptake remains unproven because Q2 Afrezza sales were soft and launch resources were reallocated toward pediatrics. [#SEC-8K-2026-08-05]
2026-12-31catalystIPF and ralinepag pipeline executionHigh impact
MNKD-201 Phase 1b data supported continued advancement, global Phase 2 enrollment is underway, and the ralinepag DPI program is targeted for an IND filing by year-end with United Therapeutics support. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology